STARLIMS Joins the Fight against Tuberculosis
Hollywood, Florida February 1, 2005, STARLIMS Corporation, the leading global provider of Laboratory Information Management Systems, (LIMS), today unveiled a joint effort with Lilly MDR-TB partnership in the battle against the expanding crisis of multi-drug resistant tuberculosis (MDR-TB), a virulent mutated type of tuberculosis (TB) that is difficult to treat, and therefore much more likely to spread.
The Lilly MDR-TB Partnership is a uniquely comprehensive initiative with the World Health Organization (WHO), the U.S. Department of Health and Human Services’ Centers for Disease Control and Prevention (CDC), Brigham and Women’s Hospital (BWH), an affiliate of Harvard Medical School, the International Council of Nurses (ICN) and Purdue University to increase the number of trained personnel and drugs available to treat the expanding crisis of MDR-TB.
Through funding from Lilly, the CDC have begun the implementation of STARLIMS as a platform for extensive laboratory–based electronic surveillance of patients resistance to drugs used for treating MDR-TB, in clinics throughout Russia and Kazakhstan.
STARLIMS is an enterprise level information system that brings together all public health laboratory activities into a single platform, offering comprehensive reporting, surveillance, and networking capabilities compatible with national and international standards. Public health solutions from STARLIMS are designed as a platform for linking between regional public health partners working under the PHIN framework, HL7 messaging protocols and using LOINC and SNOMED as the common vocabulary for test names and observations. This functionality enables cross site sample transfer and data exchange.
“The CDC and STARLIMS partnership allows us to apply LIMS technology to monitor treatment effectiveness. This is a very critical component of our whole effort to address MDR-TB”, stated. “Dr. Gail Cassell, vice president, scientific affairs and distinguished research scholar for infectious diseases, Eli Lilly and Company.
“STARLIMS was honored to be asked to join the CDC in the Lilly MDR-TB partnership that addresses one of today’s most challenging public health threats” said Isaac Friedman, president & CEO of STARLIMS Corporation. “Our specific role is to provide STARLIMS licenses and know-how necessary to implement an effective MDR-TB monitoring and surveillance infrastructure throughout a network of WHO sponsored treatment centers”.
About Lilly MDR-TB Partnership
The Lilly MDR-TB partnership is a pioneering initiative led by Eli Lilly and Company that will increase the number of trained medical personnel and drugs available to treat people with multi-drug resistant tuberculosis, an expanding global health crisis. Described as a new paradigm for addressing global public health threats, the Lilly MDR-TB Partnership is an example of Lilly’s ongoing commitment to provide “Answers That Matter.” Additional information about Lilly MDR-TB Partnership is available at www.lillymdr-tb.com.
About STARLIMS Corporation
STARLIMS Corporation delivers cost effective, easy-to-use collaborative LIMS solutions to organizations in the public health, pharmaceutical, petrochemical, forensics, food & beverage, environmental and chemical industries. Full featured and highly flexible our multilingual laboratory information management system provides complete traceability leading to regulatory compliance, without compromising process versatility.
A 15 year track record has earned us recognition for “future proofing” our customers’ investments and serving as a platform for new implementations and straightforward conversions of legacy systems. To learn more about STARLIMS please visit us at www.starlims.com
